[Anemia and its treatment in peritoneal dialysis patients] - PubMed (original) (raw)
Review
. 2005:117 Suppl 6:69-72.
doi: 10.1007/s00508-005-0486-9.
[Article in German]
Affiliations
- PMID: 16437336
- DOI: 10.1007/s00508-005-0486-9
Review
[Anemia and its treatment in peritoneal dialysis patients]
[Article in German]
Walter H Hörl. Wien Klin Wochenschr. 2005.
Abstract
The need for erythropoietin (rhuEPO) or darbepoetin-alpha and iron is lower in patients undergoing peritoneal dialysis (PD) than in patients treated with hemodialysis (HD) because blood losses are reduced, residual renal function and elimination of inhibitors of erythropoiesis are improved and inflammation is less than in HD treatment. In addition, comorbidities of PD patients are probably lower than those of HD patients, and this factor may also contribute to anemia being less in PD patients than in those on HD. Furthermore, the frequency of blood transfusions is lower in PD patients, with or without rhuEPO treatment. However, in PD patients also, anemia is associated with hospitalization rate and mortality. Anemia can be corrected by subcutaneous injections of rhuEPO-beta (1-3 times per week) or darbepoetin-alpha (once a week or twice a month). Adjuvant treatment of anemia includes correction of iron deficiency by oral or intravenous iron, androgen substitution in elderly male PD patients and adequate calcitriol supplementation. Factors that may negatively influence anemia in PD patients are inflammation, infection, antihypertensive therapy with ACE inhibitors or angiotensin II blockers and neutralizing antibodies against rhuEPO or darbepoetin-alpha.
Similar articles
- 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. Tsubakihara Y, et al. Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x. Ther Apher Dial. 2010. PMID: 20609178 - Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR. Coronel F, et al. J Nephrol. 2003 Sep-Oct;16(5):697-702. J Nephrol. 2003. PMID: 14733416 - [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC; Groupe de l'étude NESP 20000117. Kessler M, et al. Nephrol Ther. 2006 Sep;2(4):191-9. doi: 10.1016/j.nephro.2006.06.004. Epub 2006 Aug 17. Nephrol Ther. 2006. PMID: 16966064 Clinical Trial. French. - The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.
Schröder CH; European Pediatric Peritoneal Dialysis Working Group. Schröder CH, et al. Pediatr Nephrol. 2003 Aug;18(8):805-9. doi: 10.1007/s00467-003-1126-0. Epub 2003 May 15. Pediatr Nephrol. 2003. PMID: 12750985 Free PMC article. Review. - The treatment of anemia in peritoneal dialysis patients.
Lacson E Jr, Diaz-Buxo JA. Lacson E Jr, et al. Clin Nephrol. 2001 Dec;56(6):415-27. Clin Nephrol. 2001. PMID: 11770793 Review.
Cited by
- Iron supplementation and mortality in incident dialysis patients: an observational study.
Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, Weiss G. Zitt E, et al. PLoS One. 2014 Dec 2;9(12):e114144. doi: 10.1371/journal.pone.0114144. eCollection 2014. PLoS One. 2014. PMID: 25462819 Free PMC article. - The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.
Lea JP, Norris K, Agodoa L. Lea JP, et al. Am J Nephrol. 2008;28(5):732-43. doi: 10.1159/000127981. Epub 2008 Apr 24. Am J Nephrol. 2008. PMID: 18434712 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous